In emergency situations such as Covid-19, emergency use authorizations (EUA) are vital and necessary. There needs to be effective treatments and vaccines available to stop the spread of this virus. The failures like hydroxychloroquine show that the EUA process must be robust enough that the authorized products do not harm the public or entrench public distrust of medicine. There cannot be EUAs for products that do not work.
The EUA for hydroxychloroquine and its eventual revocation show the shortfalls of the current EUA process. The treatment did not help Covid-19 patients and brought potential health risks to patients. Hydroxychloroquine should never have been authorized in the first place. The approval process must be revised for the safety of the population.